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Plasma acylcarnitine 
concentrations reflect the 
acylcarnitine profile in cardiac 
tissues
Marina Makrecka-Kuka  1, Eduards Sevostjanovs1, Karlis Vilks1,2, Kristine Volska1,3,  
Unigunde Antone1, Janis Kuka1, Elina Makarova1, Osvalds Pugovics1, Maija Dambrova1,3 & 
Edgars Liepinsh1
Increased plasma concentrations of acylcarnitines (ACs) are suggested as a marker of metabolism 
disorders. The aim of the present study was to clarify which tissues are responsible for changes in the AC 
pool in plasma. The concentrations of medium- and long-chain ACs were changing during the fed-fast 
cycle in rat heart, muscles and liver. After 60 min running exercise, AC content was increased in fasted 
mice muscles, but not in plasma or heart. After glucose bolus administration in fasted rats, the AC 
concentrations in plasma decreased after 30 min but then began to increase, while in the muscles and 
liver, the contents of medium- and long-chain ACs were unchanged or even increased. Only the heart 
showed a decrease in medium- and long-chain AC contents that was similar to that observed in plasma. 
In isolated rat heart, but not isolated-contracting mice muscles, the significant efflux of medium- and 
long-chain ACs was observed. The efflux was reduced by 40% after the addition of glucose and insulin 
to the perfusion solution. Overall, these results indicate that during fed-fast cycle shifting the heart 
determines the medium- and long-chain AC profile in plasma, due to a rapid response to the availability 
of circulating energy substrates.
Acylcarnitines (ACs) are formed from carnitine and acyl-CoAs by carnitine acyltransferases in mitochondria or 
peroxisomes1,2. ACs are generally considered to be a transport form of fatty acids (C2-C26) and can be utilized for 
energy production in mitochondria or for the synthesis of endogenous molecules; they can also be transported 
from tissues to plasma. An increase in plasma AC concentration has been linked to the progression of various dis-
eases, including insulin resistance3–7 and cardiovascular diseases8–12. Since the metabolism of fatty acids, glucose 
and amino acids can yield ACs, their concentration in plasma is determined by the nutritional state and tissue- or 
organ-specific contributions. Therefore, to link a particular disease and nutrition state to the plasma AC profile, it 
is important to clarify the origin of ACs responsible for changes in the AC concentration in plasma.
The AC profile, or the concentrations of ACs with specific chain lengths, could characterize the energy metab-
olism pattern and could indicate the presence of fatty acid oxidation and organic acid metabolism disorders. In 
contrast to short-chain ACs that are produced from glucose, amino acids and fatty acid degradation, medium- 
and long-chain ACs are derived exclusively from fatty acid metabolism. Long-chain ACs are mainly synthesized 
and metabolized in mitochondria; therefore, concentrations of long-chain ACs are used as markers of mitochon-
drial fatty acid oxidation. Historically, an increased concentration of ACs has been used as a marker of incom-
plete fatty acid oxidation to diagnose inborn fatty acid oxidation defects13. However, an increased concentration 
of ACs is also observed in a fasted state when the fatty acid oxidation rate is increased14–17. Taking into account 
that long-chain fatty acids are mostly utilized by the heart and skeletal muscles14,18,19, changes in the concentra-
tions of long-chain ACs in plasma should represent the fatty acid oxidation pattern of heart and skeletal muscle 
mitochondria.
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Under physiological conditions, an organism has to switch between glucose and fatty acid metabolism based 
on the availability of substrates to maintain energy homeostasis. Circulating concentrations of substrates and 
hormones and concomitant changes in gene and protein expression determine the energy metabolism pattern in 
tissues14,20–22. It has been proposed that the plasma concentrations of ACs, particularly medium- and long-chain 
ACs, can predict the intracellular energy metabolism pattern and can be used as a marker of metabolic dysfunc-
tion3–12,23,24. However, in the studies that have suggested increased AC levels as a marker of insulin resistance, 
type 2 diabetes and cardiovascular diseases, the measurements were performed only in plasma or serum, and 
data regarding the AC content in tissues are lacking. To date, only a few studies have investigated the relationship 
between plasma and tissue AC contents15–17,23,25,26. Measurements of ACs in fed and fasted states showed that the 
plasma long-chain AC concentration reflects the AC content in cardiac tissue, but the data regarding the content 
in muscles are controversial15–17,26. These data indicate that plasma ACs relationship to the tissue ACs could be 
dependent on the metabolic condition imposed at the time of assessment. The time-dependent changes in tis-
sue AC contents after glucose administration have never been investigated. It remains unclear how the plasma 
AC profile reflects the AC content in tissues after different stimulus (glucose administration or exercise) and 
which tissues are responsible for changes in the plasma AC profile. Thus, in the present study, we investigated the 
changes in the AC profile in plasma and tissues in the fed and fasted states, as well as time-dependent changes 
during an oral glucose tolerance test. In addition, the AC effluxes were measured in isolated organ models.
Results
Effects of fasting on AC concentrations in tissues. As shown in Fig. 1, the highest AC content was 
observed in the heart (390–430 nmol/g), followed by muscles (250–350 nmol/g); the lowest contents were in 
plasma (10–25 µM) and in adipose tissues (6–8 nmol/g). Moreover, the highest amount of ACs per organ was 
found in the skeletal muscles, liver and heart (Fig. 1D,E).
Short-, medium- and long-chain AC concentrations were 2.1, 3.4, and 2.6 times higher, respectively, in plasma 
from overnight fasted animals than in plasma from fed animals (Fig. 1, Supplementary Table S2). In the heart, 
the content of medium-chain ACs was increased by only 53% (p = 0.09) (Fig. 1B), while an almost 5-fold higher 
content of long-chain ACs (Fig. 1C) was observed in the fasted state compared with the fed state samples. In 
skeletal muscle tissues, the acetylcarnitine content was 24% lower in the fasted animals than in the fed animals 
(Fig. 1A), while the medium- and long-chain AC contents in muscle were 3.5 and 2.9 times higher, respectively, in 
the fasted state compared with the fed state (Fig. 1B,C). In the liver, overnight fasting induced a 21–32% decrease 
in acetyl- and medium-chain AC contents (Fig. 1A,B), whereas a 2.5-fold increase in the long-chain AC content 
was observed (Fig. 1C). The acetylcarnitine content in epidydimal adipose tissues was 30% lower in the fasted 
state than in the fed state (Fig. 1A), while the long-chain AC content did not differ significantly between the fed 
and fasted states (Fig. 1C). Overnight fasting induced a decrease of 40% in the acetylcarnitine content in kidney 
tissues (Fig. 1A), whereas the medium- and long-chain AC contents were not changed (Fig. 1B,C). Interestingly, 
the amounts of medium- and long-chain ACs in plasma were comparable to the amount of ACs in the heart 
(Fig. 1D,E), indicating that changes in AC content in the heart could determine changes in the AC profile in 
plasma. Taken together, these results demonstrate that the most pronounced difference in AC concentration 
between the fed and fasted states was in tissues that exhibit the most pronounced metabolic flexibility, such 
as the heart, skeletal muscles and liver. Since changes in plasma AC concentrations, particularly medium- and 
long-chain ACs, reflected changes in AC content in these tissues, plasma AC concentrations could be a valid 
marker for AC tissue content.
AC concentration during an oral glucose tolerance test (OGTT). To evaluate whether the plasma 
AC profile can be used as a marker of AC content in tissues, the AC content was measured during an OGTT in 
the heart, hindlimb muscles and liver, and the possible association of plasma AC concentrations with AC content 
in these tissues was studied. During the OGTT, a significant increase in glucose and insulin concentrations was 
observed 30 min after glucose administration, followed by a rapid decrease in glucose and insulin concentra-
tions almost to the baseline level (Fig. 2A,B). In contrast to glucose and insulin concentrations, the levels of all 
ACs in plasma were decreased 30 min after glucose administration and then gradually increased (Fig. 3A–C, 
Supplementary Table S3).
Since short-chain ACs are of mixed origin (glucose, amino acid and fatty acid metabolism), the changes in 
their contents in tested tissues were negligible during the OGTT (Fig. 3D,G,J, Supplementary Tables S4–6). In the 
heart, 30 min after the administration of glucose, the contents of medium- and long-chain ACs were significantly 
decreased and slowly increased afterwards (Fig. 3E,F, Supplementary Table S4). No such changes in skeletal mus-
cles and liver were observed (Fig. 3H,I,K,L), suggesting that the concentration of medium- and long-chain ACs in 
plasma reflects the changes in AC content in the heart. This was further confirmed by measurements of palmitate 
oxidation and long-chain AC efflux in the heart. In isolated rat hearts, the addition of glucose and insulin to the 
perfusion solution decreased palmitate oxidation by 30% (Fig. 4A) and decreased the medium- and long-chain 
AC efflux from tissues by 43% and 35%, respectively (Fig. 4B,C). These results demonstrate that the heart is able 
to react immediately to the changes in circulating substrates and switch its energy metabolism from fatty acid oxi-
dation to glucose oxidation. Accordingly, the medium- and long-chain AC profile in the heart reflects changes in 
energy metabolism. Moreover, these results indicate that the heart could determine changes in plasma medium- 
and long-chain AC concentrations during the transition from fasted to fed state.
In contrast to the heart, the skeletal muscles did not respond to short-term changes in plasma glucose and 
insulin concentration. The fatty acid metabolism and corresponding contents of medium- and long-chain ACs 
were not changed during the OGTT (Fig. 3H,I, Supplementary Table S5). This fact was supported by an indirect 
calorimetry experiment in mice. The RER remained decreased (0.7) after glucose administration (Fig. 4D), indi-
cating that skeletal muscles cannot rapidly switch from fatty acid to glucose metabolism. Moreover, in contrast 
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to heart, in mice isolated skeletal muscle model, we did not observe any efflux of medium- (data not shown) and 
long-chain ACs (Fig. 4E), indicating that even the contracting skeletal muscles do not contribute to plasma AC 
pool.
In liver tissues, a significant increase in medium- and long-chain AC content was observed 30 min after glu-
cose administration (Fig. 3K,L, Supplementary Table S6). Changes in medium- and long-chain AC contents in 
the liver (Fig. 3K,L) that did not correspond to changes in plasma AC content (Fig. 3B,C) were observed after-
wards, indicating that the liver does not determine the changes in the plasma medium- and long-chain AC profile 
observed during the OGTT.
AC concentrations in plasma, skeletal muscles and heart after exercise. Since skeletal muscles 
contain high amount of medium- and long-chain ACs and could contribute to plasma AC pool under conditions 
of the increased energy demand, we determined AC profile in plasma, skeletal muscles and heart after moderate 
intensity exercise. As seen in Fig. 5, after exercise, the medium- and long-chain AC contents in skeletal muscles 
were increased 1.8 and 2 times, respectively, compared to AC content in sedentary control group; however, no 
difference in medium- and long-chain AC concentrations was found in heart and plasma. These results support 
observation that changes in plasma medium- and long-chain ACs do not reflect changes in AC profile in skeletal 
muscles.
Figure 1. Acylcarnitine (AC) concentrations and amounts in plasma and different organs in the fed and fasted 
states. During fasting, the acetylcarnitine concentration was significantly increased in plasma but decreased 
in the skeletal muscles, kidney and adipose tissues (A). The medium-chain AC concentration was increased 
in plasma, heart and skeletal muscles and decreased in the liver (B) in fasted animals. The long-chain AC 
concentration was significantly higher in plasma, heart, skeletal muscles and liver in the fasted group. The 
highest amount of medium-chain (D) and long-chain (E) ACs per organ was observed in the heart, skeletal 
muscles and liver; moreover, the content of ACs in the plasma was comparable to the AC content in the heart. 
The results are presented as the average values ± SEM of 7 animals. *Indicates a significant difference compared 
with the fed group (Student’s t-test, P < 0.05).
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Discussion
In the present study, we demonstrated that the most pronounced difference in AC content between the fed and 
fasted states was observed in tissues that are metabolically flexible. In addition, we showed that the amount of ACs 
in plasma is comparable with the heart tissue content of long- and medium-chain ACs and it can be easily affected 
by a metabolic switch from fatty acid to glucose oxidation in the heart. Moreover, the observed simultaneous 
changes in medium- and long-chain AC content both in plasma and in the heart after glucose administration 
indicate that plasma medium- and long-chain AC concentrations reflect the content of ACs found in the heart.
During fasting, the heart produces energy almost exclusively from fatty acid oxidation14,18; thus, a substan-
tial increase in long-chain AC content is observed. Since the heart has limited stores of energy substrates27,28, it 
rapidly switches to the available circulating substrates. Thus, it is not surprising that immediately after glucose 
administration, a decrease in long- and medium-chain AC contents in the heart is observed as a result of the 
energy metabolism switch from fatty acid to glucose oxidation. Later, when the plasma glucose concentration 
decreases, the heart switches back to fatty acid oxidation, which results in increased cardiac contents of medium- 
and long-chain ACs (Fig. 6).
The energy metabolism pattern in skeletal muscles is similar to that in the heart. Skeletal muscles oxidize 
both fatty acid and glucose, and fatty acid metabolism is predominant when glucose reserves are depleted19,29. A 
corresponding increase in skeletal muscle AC content is also observed in the case of prolonged fasting17. During 
the OGTT, skeletal muscles did not react to glucose administration, while we observed a gradual increase in 
long-chain AC content 4–6 h after the OGTT. Since long-chain ACs play an active role in the regulation of energy 
metabolism and determine the metabolic pattern in muscles and the heart15,23,30,31, the increase in long-chain 
AC content during prolonged fasting hinders muscles from immediately switching to glucose metabolism; this 
metabolic state is described as transient postprandial insulin resistance17,32,33. In addition, the exercise-induced 
increase in muscle medium- and long-chain AC content did not induce any changes in concentrations of these 
ACs in plasma. In skeletal muscles long-chain AC content is 10–20-fold higher than in plasma; this difference 
should be sufficient to ensure efflux of long-chain ACs. It could be assumed that in case of any efflux of long-chain 
ACs from muscles, plasma AC concentration is maintained by increased uptake of ACs by other organs. However, 
in line with previous studies in humans34 and porcine model35, we did not observe any significant long-chain AC 
efflux from isolated mice contracting skeletal muscle. Overall, data suggest that there is negligible long-chain AC 
efflux from muscles under physiological conditions. Taking together these results show that the concentration of 
medium- and long-chain ACs in plasma does not reflect the muscle AC content shortly after glucose administra-
tion or after exercise.
Figure 2. The concentrations of glucose and insulin in plasma during an oral glucose tolerance test. A 
significant increase in glucose (A) and insulin (B) concentration in plasma was observed after oral glucose 
administration. The results are presented as the average values ± SEM of 5 animals. *Indicates a significant 
difference compared with the baseline group (one-way ANOVA with Tukey’s post-test, P < 0.05).
www.nature.com/scientificreports/
5ScientiFic REPORtS | 7: 17528  | DOI:10.1038/s41598-017-17797-x
Several studies have investigated the role of the liver in the regulation of the plasma AC pool34,35. It has been 
suggested that the increased level of long-chain ACs observed in the liver during fasting reflects an increase in 
fatty acid activation and subsequent oxidation16. In our study, we observed that fasting induces an increase in the 
liver content of long-chain ACs, but not medium-chain ACs, indicating that changes in the AC profile character-
ize the uptake rate of fatty acids and their metabolites rather than fatty acid oxidation in the liver. This is in line 
with previous observations of long-chain AC uptake by the liver in humans during overnight fasting34. Moreover, 
a recent study in liver-specific carnitine palmitoyltransferase 2 knock-out mice demonstrated that despite a dra-
matic increase in the long-chain AC content in the liver, the concentration of long-chain ACs in plasma was not 
Figure 3. Acylcarnitine (AC) concentrations in plasma and different organs during an oral glucose tolerance 
test (OGTT). The concentrations of ACs (acetyl-(C2; A), medium- (MC; B) and long-(LC; C) chain) in plasma 
were decreased 30 min after glucose administration and then increased. The changes in the acetylcarnitine 
contents in the heart (D), skeletal muscles (G) and liver (J) were negligible during the OGTT. In the heart, 
30 min after the administration of glucose, the contents of medium- (E) and long-chain (F) ACs were 
significantly decreased and slowly increased afterwards. After glucose administration, the contents of medium- 
(H) and long-chain (I) ACs increased in muscles, while in the liver, the contents of medium-(K) and long-chain 
(L) ACs varied over time. The results are presented as the average values ± SEM of 5 animals. *Indicates a 
significant difference from the baseline (one-way ANOVA with Tukey’s post-test, P < 0.05).
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affected36. Thus, it seems that the liver actively takes up and accumulates long- and medium-chain ACs rather 
than releasing them into the plasma.
It has been suggested that short-chain ACs in plasma are released from the liver, while medium-chain ACs are 
released from the liver and muscles34,35. Since in the heart, fatty acids are the preferred substrate for ATP produc-
tion14,18,27, it has been suggested that long-chain ACs may be released from the heart34; however, no evidence for 
this has ever been provided. In the present study, we demonstrated that changes in the long-chain AC concen-
tration in plasma during an OGTT reflect changes in long-chain ACs in the heart, but not in muscle or the liver. 
In addition, the medium- and long-chain AC efflux from the heart, but not from skeletal muscles, was observed 
ex vivo. Moreover, the amount of medium- and long-chain ACs in the heart is comparable to the amount of ACs 
found in plasma. Taken together, these data indicate that changes in the long-chain AC content in the heart can 
determine changes in the medium- and long-chain AC profile observed in plasma (Fig. 6) and that the heart is the 
major contributor to the long-chain AC pool in plasma.
The ability to switch between available energy substrates is crucial for cell functioning. Impaired metabolic 
flexibility is involved in the development of metabolic disorders such as insulin resistance and heart failure20,21,37. 
It has been demonstrated that the accumulation of lipid intermediates (diacylglycerols, ceramides, acyl-CoA, 
etc.) in the liver, skeletal muscle and heart induces metabolic inflexibility caused by mitochondrial dysfunction, 
activates inflammation pathways and impairs insulin signaling19,38,39. Though for decades ACs were thought to 
be only a transport form of acyl-moieties into mitochondria, recent studies have elucidated the active role of ACs 
in the regulation of energy metabolism and proposed AC accumulation as a link to insulin resistance15,26,30,31. 
Therefore, plasma AC concentration changes could be a valuable diagnostic marker for insulin resistance.
The potential limitations of our study is that OGTT characterizes the organ response to insulin stimulus 
induced by glucose administration, but not overall metabolic flexibility as transition from fasted to fed state. The 
OGTT is common method used in clinics to diagnose insulin resistance in peripheral tissues. Our data indicate, 
that addition of AC profile measurements in plasma during OGTT could be used to evaluate organ, particularly 
heart, specific insulin resistance; however, further studies are needed to investigate the potential application of AC 
profile measurements in the diagnostics of tissue specific insulin resistance.
A disturbed plasma AC profile is used as a marker for incomplete fatty acid oxidation to diagnose inher-
ited disorders and metabolic inflexibility4,13,24. Only a few studies have investigated the association between the 
Figure 4. The energy metabolism pattern in the heart and muscles. In isolated rat hearts, the addition of 
glucose and insulin to a fatty acid (FA) perfusion solution significantly decreased palmitate oxidation (A) and 
medium- (B) and long-chain (C) AC efflux from tissues. Indirect calorimetry measurements (D) showed that 
after glucose administration, there were no changes in RER (0.7), indicating that muscles cannot rapidly switch 
from fatty acid to glucose metabolism. Time-dependent changes in long-chain AC concentration in buffer show 
that, in contrast to heart, in isolated mice contracting skeletal muscle model there is no significant efflux of long-
chain ACs (E). The results are presented as the average values ± SEM of 6 hearts (A–C) or 5(D) or 4 (E) mice. 
*Indicates a significant difference from the control conditions (A – FA buffer; B – fasted state) (Student’s t-test 
or one-way ANOVA with Tukey’s post-test, P < 0.05).
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plasma AC profile and tissue AC concentrations16,17. In line with previous studies16,17, in the present study no 
association between the plasma AC profile and the AC profile in muscles and liver was observed during OGTT 
or after exercise. Nonetheless, the concentration of medium- and long-chain ACs in plasma reflect the AC profile 
in the heart, probably due to rapid energy turnover in the heart. Compared with other organs, the heart has the 









































Figure 5. The medium- (A) and long-chain (B) acylcarnitine (AC) content in plasma, heart and skeletal muscle 
tissues after exercise. The exercise induced significant increase in medium- and long-chain AC content in 
muscles, while AC concentration in plasma and heart was not changed. The results are presented as the average 
values ± SEM of 6-7 animals. *Indicates a significant difference compared with the control group (Student’s 
t-test, P < 0.05).
Figure 6. The time-dependent changes in glucose, insulin and long-chain acylcarnitine (AC) concentrations 
in plasma and in the long-chain AC content in the heart after glucose administration. The administration of 
glucose induces an increase in glucose (red line) and insulin (green line) concentrations and a simultaneous 
decrease in the long-chain AC concentration in the heart (black line) and plasma (blue line), indicating that 
the heart switches to glucose metabolism for energy production. Afterwards, when plasma glucose and insulin 
concentrations decrease, an increase in long-chain AC concentrations in the heart and plasma is observed, 
indicating that the heart switches back to fatty acid oxidation.
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fed state is higher than that in other tissues in the fasted state. Thus, if AC flux from tissues to plasma depends 
on intracellular concentration, the highest possible efflux of medium- and long-chain ACs to plasma could be 
from the heart. In addition, AC content-related flux changes might be non-linear. This could explain why, despite 
being relatively small, changes in the medium- and long-chain AC content in the heart during a fed-fast cycle can 
significantly contribute to the plasma AC pool. Notably, in patients with heart failure, which is characterized by 
cardiac metabolic inflexibility, elevated concentrations of circulating long-chain ACs are associated with impaired 
cardiorespiratory capacity and an increased risk of adverse clinical outcomes8. Thus, the plasma medium- and 
long-chain AC concentration can be used as a marker of the cardiac energy metabolism pattern (Fig. 6) and the 
risk of cardiovascular diseases.
In conclusion, our results demonstrate that the heart is a major contributor to plasma AC concentration 
changes, particularly medium- and long-chain ACs. Moreover, the plasma AC profile can be used as an indicator 
of metabolic flexibility in cardiac tissue.
Methods
Animals and treatments. Fifty-six male Wistar rats weighing 320–350 g and 21 male CD1 mice (35–38 g) 
were obtained from the Harlan Laboratories BV (Netherlands) and adapted for two weeks prior to the experi-
ments. All animals were housed under standard conditions (21–23 °C, 12 h light/dark cycle, relative humidity 
45–65%) with unlimited access to food (R70 diet, Lactamin AB, Kimstad, Sweden) and water. To avoid anaes-
thesia effect on AC profile in tissues40, for tissue sample collection animals were sacrificed by decapitation. The 
experimental procedures were performed in accordance with the guidelines of the European Community as well 
as local laws and policies, and the procedures were approved by the Latvian Animal Protection Ethical Committee 
of the Food and Veterinary Service, Riga, Latvia. All studies involving animals were reported in accordance with 
the ARRIVE guidelines41,42.
Animals were randomly separated into two experimental groups, fed (n = 7) and fasted (n = 7). The rats in 
the fed group had unlimited access to food, whereas those in the fasted group were deprived of food for 18 h 
prior to the start of the experiment. Fasting was started at the end of the light phase. The animals were sacrificed, 
and samples of plasma and heart, hindlimb muscle, liver, kidney and epidydimal adipose tissues were collected. 
Thirty additional rats were used for the oral glucose tolerance test (OGTT) experiment (n = 5 per time point). 
The rats were fasted overnight for 18 h, and then a glucose solution (0.5 g/kg of body weight) was administered per 
os. Samples (plasma and heart, hindlimb muscle and liver tissues) were collected 0, 0.5, 1, 2, 4 and 6 h after glu-
cose administration. For the exercise experiment, 21 wheels forced exercise/walking wheel apparatus (PsymCon 
Model 35500, Lafayette Instrument, Lafayette, USA) was used. Before the experiment, mice (n = 14) were adapted 
to exercise for one week: on the first and second day mice walked 30 min at a speed of 3 m/min, on the third day 
they walked 40 min at a speed of 3.5 m/min, on the fourth day they walked 50 min at a speed of 4 m/min and on 
the fifth day they walked 60 min at a speed of 5 m/min. Mice were fasted overnight for 18 h. To ensure low AC 
concentration in plasma and high AC content in skeletal muscles that could enhance AC transport from muscles 
to plasma, before the experiment glucose at a dose of 0.3 g/kg was administrated intraperitoneally. After 30 min, 
mice (n = 7) were placed in the forced running wheel and were running 1 h at a speed of 10 m/min. Other 7 mice 
were used as a sedentary control group. After the experiment, plasma, heart and hindlimb muscles were collected. 
All samples were stored at −80 °C until analysis. An additional 12 rats were used for the isolated heart experi-
ment. Five mice were used for the indirect calorimetry assay. An additional 4 mice were used for the isolated 
skeletal muscle experiment.
Determination of the AC profile in plasma and tissues. The AC contents in the rat plasma and 
tissue samples were measured using ultra-performance liquid chromatography-tandem mass spectrome-
try (UPLC-MS-MS) as described by Kivilompolo et al.43 with some modifications. The tissue extraction was 
performed as previously described44 with modifications. Briefly, 0.4 ml of freshly prepared 100 mM potassium 
phosphate monobasic (KH2PO4, pH 4.9) and 1 ml of acetonitrile/2-propanol/methanol 3:1:1 (v/v) was added to 
100 mg of tissue or 100 µl of plasma. The sample was sonicated for 30 s and centrifuged at 16000 g for 10 min. The 
supernatant was used for UPLC MS/MS analysis. A Waters Acquity UPLC H-Class chromatograph was coupled 
to a Waters Xevo TQ-S tandem mass spectrometer. Chromatographic separation was performed on a Waters 
Acquity UPLC BEH Hilic (2.1 × 100 mm, 1.7 µm) column in gradient mode. Solvent A was 10 mM ammonium 
acetate with 0.2% formic acid in water, and solvent B was acetonitrile. The initial mobile phase composition 
was 10% solvent A and was linearly increased to 20% solvent A over 7 minutes. The total run time with column 
flush and re-equilibration was 10 minutes. The column temperature was 30 °C, and the flow rate was 0.5 ml/min. 
Data acquisition was performed in positive electrospray ionization (ESI+) and multiple reaction monitoring 
(MRM) mode. The ion source parameters were as follows: source temperature, 120 °C; capillary voltage, 2.5 kV; 
desolvation gas temperature, 600 °C; desolvation and cone gas flow, 800 L/h and 150 L/h, respectively. The MRM 
transitions with cone and collision energy values are presented in Supplementary Table S1. The concentrations 
of ACs were measured against a nine-point standard curve of C4-C18 and C2-C3 ACs within a range of 0.01 nM 
to 20 nM and 0.2 nM to 200 nM in an analytical sample, respectively. The derivates with carbon chain C2-C5, 
C6-C12, C14-C18 were considered as short-, medium- and long-chain ACs, respectively. The concentration of 
ACs was expressed µM for plasma and nmol per mg of wet weight for tissues.
In addition, the amount of ACs per organ was calculated taking into account the average weight of whole 
organ or plasma volume45,46: concentration (nmol/g or µM) × organ weight or plasma volume.
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Determination of the glucose and insulin concentrations in plasma. The plasma glucose and insu-
lin concentrations were determined using a kit from Instrumentation Laboratory and a Rat/Mouse Insulin ELISA 
kit (Millipore, Billerica, USA).
Determination of the energy metabolism pattern in heart and muscles. The rate of radiolabeled 
palmitate oxidation was measured in fasted Wistar rat hearts as previously described14 with the modifications 
indicated below. Briefly, rats were anesthetized using sodium pentobarbital (60 mg/kg i.p.) with the concomitant 
administration of heparin (1000 IU/kg). The hearts were excised and retrogradely perfused with the respective 
oxygenated (95% O2 - 5% CO2) perfusion solutions via the aorta at a constant pressure of 70 mm Hg. The hearts 
were perfused with the respective non-labeled oxygenated Krebs-Henseleit (KH) buffer solution (118 mM NaCl, 
4.7 mM KCl, 2.52 mM CaCl2, 1.64 mM MgCl2, 24.88 mM NaHCO3, 1.18 mM KH2PO4 and 0.05 mM EDTA, pH 
7.4 at 37 °C) supplemented with palmitate, glucose and insulin for 30 min. Fatty acid buffer was used to mimic 
the fasted state and contained 0.8 mM sodium palmitate bound to 2% BSA, 5 mM glucose, and 0.3 ng/ml insulin. 
To study the transition from fasted to fed state, fatty acid buffer was supplemented with additional glucose and 
insulin at final concentrations of 10 mM and 3 ng/ml, respectively. After 1 h of perfusion, the solution was then 
switched to the respective oxygenated radiolabeled KH buffer solution for 10 min. Palmitate oxidation was deter-
mined by measuring 3H2O released from [9,10-3H]palmitate (specific activity, 60 Ci/mmol). In addition, the AC 
profile was measured in the collected perfusate to determine the AC efflux from heart tissues.
Since skeletal muscle metabolism is the major determinant of whole-body energy expenditure47,48, the skeletal 
muscle energy metabolism pattern was determined using indirect gas calorimetry. The PhenoMaster system for 
mice (TSE, Germany), with automated food/liquid access control units and an indirect gas calorimetry system, 
was used to monitor 24 h changes in energy metabolism. The mice were adapted to the PhenoMaster system for 
72 h before the experiment. Adapted mice were fasted overnight, and glucose (0.5 mg/kg i.p.) was then adminis-
tered. The rates of oxygen consumption (VO2) and carbon dioxide production (VCO2) were monitored to esti-
mate the respiratory exchange rate (RER), an indicator of the energy metabolism pattern in skeletal muscles.
For isolated muscle experiment, mice fasted overnight were euthanized by cervical dislocation. Hindlimbs of 
the animal were sprayed with 70° ethanol and pinned on a support board. The skin was cut through the entire 
length of the limb and the underlying muscles were exposed. Fascia and tibialis anterior muscle were carefully 
removed and extensor digitorum longus muscle was exposed. A loop of surgical silk thread was tied around the 
distal tendon of the muscle and a platin hook was tied to the proximal end of the muscle using surgical thread. 
Both tendons were cut and muscles were transferred to ice-cold KH buffer solution. Further the muscles were 
attached to a force transducer and positioned between two platinum rings so that the muscle could be stimulated 
electrically and the resultant force response recorded. Muscles were stretched to an optimal level and stimu-
lated with supra-maximal voltage. The experiment was performed using KH buffer solution supplemented with 
0.8 mM sodium palmitate bound to 2% BSA, 5 mM glucose, and 0.3 ng/ml insulin. Muscles were allowed to adapt 
to for 30 min, then every 10 min for 30 min the buffer solution was collected to determine the AC efflux from 
muscle tissues.
Statistical analysis. All data are expressed as the mean ± standard error of the mean (SEM). For statistical 
analysis, Student’s t-test or a one-way ANOVA with Tukey’s post-test were used. P values less than 0.05 were con-
sidered to be statistically significant. The sample size was not sufficient to perform statistical correlation analysis. 
Statistical calculations were performed using Prism 5.03 software (GraphPad, San Diego, California).
Data availability. The datasets generated during and analysed during the current study are available from 
the corresponding author on reasonable request.
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